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ABSTRACT
Background: There is growing interest in the potential
utility of molecular diagnostics in improving the
detection of life-threatening infection (sepsis).
LightCycler SeptiFast is a multipathogen probe-
based real-time PCR system targeting DNA sequences
of bacteria and fungi present in blood samples
within a few hours. We report here the protocol of the
ﬁrst systematic review of published clinical
diagnostic accuracy studies of this technology when
compared with blood culture in the setting of
suspected sepsis.
Methods/design: Data sources: the Cochrane
Database of Systematic Reviews, the Database of
Abstracts of Reviews of Effects (DARE), the Health
Technology Assessment Database (HTA), the NHS
Economic Evaluation Database (NHSEED), The
Cochrane Library, MEDLINE, EMBASE, ISI Web of
Science, BIOSIS Previews, MEDION and the Aggressive
Research Intelligence Facility Database (ARIF). Study
selection: diagnostic accuracy studies that compare the
real-time PCR technology with standard culture results
performed on a patient’s blood sample during the
management of sepsis. Data extraction: three reviewers,
working independently, will determine the level of
evidence, methodological quality and a standard data
set relating to demographics and diagnostic accuracy
metrics for each study. Statistical analysis/data
synthesis: heterogeneity of studies will be investigated
using a coupled forest plot of sensitivity and speciﬁcity
and a scatter plot in Receiver Operator Characteristic
(ROC) space. Bivariate model method will be used to
estimate summary sensitivity and speciﬁcity. The
authors will investigate reporting biases using funnel
plots based on effective sample size and regression
tests of asymmetry. Subgroup analyses are planned for
adults, children and infection setting (hospital vs
community) if sufﬁcient data are uncovered.
Dissemination: Recommendations will be made to
the Department of Health (as part of an open-access
HTA report) as to whether the real-time PCR
technology has sufﬁcient clinical diagnostic accuracy
potential to move forward to efﬁcacy testing during the
provision of routine clinical care.
Registration: PROSPEROdNIHR Prospective
Register of Systematic Reviews (CRD42011001289).
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ARTICLE SUMMARY
Article focus
- To describe the plans of a systematic review aimed
at determining the diagnostic accuracy of a new
real-time PCR technology (LightCycler Septi-
Fast), designed to detect bloodborne pathogens in
the setting of life-threatening infection (sepsis).
- To highlight the unmet need for accurate and
rapid infection diagnostics in the setting of life-
threatening infection (sepsis).
Key messages
- The study will provide the ﬁrst independent
systematic review of clinical validity studies of
multiplex real-time PCR technology aimed at
detecting circulating pathogen DNA straight from
blood in the setting of suspected life-threatening
infections (sepsis).
- Based on the results of this study, independent
recommendations will be made to the UK’s
Department of Health to help determine whether
the real-time PCR technology has sufﬁcient clinical
diagnostic accuracy to move forward to efﬁcacy
testing during the provision of routine clinical care.
Strengths and limitations
- The systematic review is focused on a single
Conformite ´ Europe ´enne (CE)-marked real-time
PCR technology designed for use in the setting
of life-threatening infection (sepsis)
- The systematic review is non-commercial and has
been planned systematically by a multidisciplinary
team of experts, working on behalf of the key
stakeholders within a nationalised healthcare system.
- Current clinical infection diagnostic reference
standards may not have high diagnostic accuracy
in all clinical settings and with all infections
Dark P, Wilson C, Blackwood B, et al. BMJ Open 2012;2:e000392. doi:10.1136/bmjopen-2011-000392 1
Open Access ProtocolINTRODUCTION
Sepsis is the clinical syndrome resulting from a host’s
systemic inﬂammatory response to infection.
1 When
severe, it is associated with considerable mortality and is
a major international healthcare problem.
2 Conﬁrma-
tion of sepsis requires objective evidence for infection,
3
which should always include an attempt at microbiolog-
ical identiﬁcation of live pathogens from blood samples
by culture techniques.
34However, culture routinely
takes several days before a positive result is available and
at least 5 days to determine that a specimen is culture
negative.
5 This temporal separation between initial
clinical suspicion and conﬁrmation of infection
routinely results in the early and sustained delivery of
potent broad spectrum antibiotics aimed at covering the
most likely pathogens as a ‘safety ﬁrst’ strategy because
delay in appropriate antimicrobial therapy is associated
with increased mortality.
67The inevitable consequence
is unnecessary antibiotic prescription, which is associated
with the development of antimicrobial resistance (eg,
MRSA), Clostridium difﬁcile infection as well as a range of
avoidable adverse effects, and acquisition costs, of anti-
microbial drug use.
8 This is driven by a lack of access to
time-critical high-speciﬁcity biomarkers of infection in
critical care
9 where overwhelming systemic inﬂamma-
tion of the body is a common occurrence and is often
not caused by infection (it may, eg, be caused by trauma,
blood transfusion, pancreatitis).
10 There is therefore an
urgent need to develop techniques that can provide
accurate diagnostic information within hours of clinical
signs appearing and so allow more informed use of
antibiotic therapy at an early stage.
There is growing interest in the potential of real-time
PCR technology to address this problem based on its
ability to detect minute amounts of pathogen DNA in
patient blood samples with results available within
4e6h .
11 Proof of concept studies have focused on two
approaches using PCR for genomic ampliﬁcation with
either (1) broad range detection of bacterial or fungal
DNA with universal primers, followed by species identi-
ﬁcation using a post-PCR technique such as gene
sequencing or electrospray mass spectrometry or (2)
using species-speciﬁc hybridisation probes that provide
direct conﬁrmation of the species present.
12 Intuitively
the latter approach would seem to have the greatest
clinical utility assuming an appropriate pathogen panel
can be established.
While the laboratory analytical sensitivity and speci-
ﬁcity of these techniques for the detection of pathogen
DNA in blood has been evaluated,
12 there remains an
acknowledged lack of clinical trial data to deﬁne the
diagnostic reliability of such tests in patients who
develop a systemic inﬂammatory response due to
suspected infection. This has been due in part to the lack
of standardised technology platforms that meet accepted
regulatory standards for clinical diagnosis.
SeptiFast, manufactured by Roche Diagnostics, GmbH,
Mannheim, Germany and run on their real-time PCR
instrument (the LightCycler), is the ﬁrst real-time PCR-
based system to be awarded a Conformite ´ Europe ´enne
(CE) mark for pathogen detection and identiﬁcation in
suspected bloodstream infection
12 13 and, to date, the
most intensively investigated in clinical cohort studies.
The system uses a multiplex approach, which allows
detection of 25 of the most common pathogen species
causing bloodstream infection in a single blood sample
(table 1). Identiﬁcation of the pathogens is based on the
use of species-speciﬁc probes targeting the internal
transcribed spacer region between the 16S and 23S areas
of ribosomal DNA of bacteria and between the 18S and
5.8S ribosomal regions of the fungal genome. This real-
time PCR technology has been extensively assessed at the
laboratory level on clinical isolates and shown to have
excellent analytical speciﬁcity and exclusivity, conﬁrming
its analytical validity.
13 An EU registration study
(unpublished), undertaken as part of the CE-marking
process, investigated 278 critically ill patients with
suspected sepsis from Denmark, Germany and Italy.
Roche Diagnostics reported that the molecular test
conferred a high diagnostic speciﬁcity and a 3- to 10-fold
higher sensitivity when compared with conventional
blood culture technology. Since this study, numerous
commercial clinical diagnostic studies have been
reported, predominantly focused on suspected sepsis. In
addition, a large, independent, multicentre, level III
clinical diagnostic accuracy study of this real-time PCR
technology is currently recruiting
14 as part of our
detailed National Institute of Health Research (NIHR)
Health Technology Assessment (HTA)-funded
programme to assess real-time PCR technologies in
sepsis diagnosis, treatment and outcome. A small
number of newer emerging CE-marked PCR technolo-
gies are also currently available that can detect pathogen
DNA rapidly in blood samples without the need for pre-
culture, either using an all-pathogen approach without
simultaneous speciation (eg, SepsiTest; Molzym GmbH,
Bremen, Germany) or by using a multiplex approach
based on a wide pathogen panel (eg, VYOO; SIRS-LAB
GmbH, Jena, Germany). Compared with SeptiFast, the
current number of clinical diagnostic studies using these
technologies is very limited. Therefore, at this time, and
as part of our independent HTA clinical studies,
14 we
describe here the protocol of a systematic review focused
on the diagnostic test accuracy of LightCycler SeptiFast
for pathogen detection and identiﬁcation in the blood
of patients with suspected sepsis. This systematic review
has been registered with PROSPEROdthe NIHR Inter-
national Prospective Register of Systematic Reviews
(CRD42011001289).
15
METHODS
Inclusion criteria of studies
Participants
Patients suspected of developing sepsis, including adults
and children, who require blood cultures irrespective of
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suspected community or hospital acquired infection.
Target conditions
Sepsis, including severe sepsis and septic shock.
16
Index test
LightCycler SeptiFast as the index test on blood for the
detection and identiﬁcation of bacterial and fungal
pathogens.
13
Comparator test (reference standard)
Blood cultures used as the reference test and under-
pinning routine clinical practice.
5 All diagnostic metrics
will be reported using this reference standard. Clearly,
there could be limitations to this standard, particularly
in the setting of intercurrent antimicrobial therapy.
However, we do not know the full extent of this problem
or indeed whether studies have deliberately included or
excluded such patients. In the absence of a straightfor-
ward and internationally agreed approach to an alter-
native reference standard at present, we believe that this
is the most robust approach and is consistent with
methods currently used in independent HTA clinical
studies in this setting.
14
Types of studies
We will include any clinical diagnostic accuracy study
that compares the index real-time PCR test with standard
culture results performed on a patient’s blood sample
during the management of sepsis.
Search methods for identifying studies
Electronic searches
We will search the Cochrane Database of Systematic
Reviews, the Database of Abstracts of Reviews of
Effects (DARE), the Health Technology Assessment
Database (HTA), the NHS Economic Evaluation Data-
base (NHSEED), The Cochrane Library, MEDLINE,
EMBASE, ISI Web of Science, BIOSIS Previews,
MEDION and the Aggressive Research Intelligence
Facility database (ARIF). The CE mark for the index test
was announced in January 2006; therefore, this system-
atic review will only consider publications from this date
in humans. There will be no language restrictions in the
electronic search for trials.
Search terms/search strategy
Speciﬁc search strategies will be developed for each
electronic database, commencing with MEDLINE
(table 2). The MEDLINE strategy will be adapted for
each subsequent database and search yields reported
and compared between databases.
Table 1 Pathogens detectable using the LightCycler SeptiFast test
Gram-negative bacteria Gram-positive bacteria Fungi
Escherichia coli Staphylococcus aureus Candida albicans
Klebsiella (pneumoniae/oxytoca) Coagulase-negative staphylococci* Candida tropicalis
Serratia marcescens Streptococcus pneumonia Candida parapsilosis
Enterobacter (cloacae/aerogenes) Streptococcus spp.y Candida glabrata
Proteus mirabilis Enterococcus faecium Candida krusei
Acinetobacter baumannii Enterococcus faecalis Aspergillus fumigatus
Pseudomonas aeruginosa
Stenotrophomonas maltophilia
*Single probe detects a group of staphylococcal pathogens including S epidermidis, S haemolyticus.
ySingle probe detects a group of streptococcal pathogens including S pyogenes, S agalacticae, S mitis.
Table 2 MEDLINE search strategy
#1 sepsis.mp. or exp Sepsis/
#2 septic shock.mp. or Shock, Septic/
#3 fung?emia.mp. or Fungemia/
#4 bacter?emia.mp. or Bacteremia/
#5 blood?stream infection$.mp.
#6 blood poison$.mp.
#7 Systemic Inﬂammatory Response Syndrome/
or SIRS.mp.
#8 septic?emia.mp.
#9 "severe sepsis".mp.
#10 (presumed adj4 sepsis).mp.
#11 (suspected adj4 sepsis).mp.
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
or #9 or #10 or #11
#13 PCR.mp. or Polymerase Chain Reaction/
#14 SeptiFast.mp.
#15 LightCycler.mp.
#16 multiplex PCR.mp.
#17 real time PCR.mp.
#18 real?time PCR.mp.
#19 Molecular Diagnostic Techniques/ or molecular
diagnosis.mp.
#20 molecular identiﬁcation.mp.
#21 #13 or #14 or #15 or #16 or #17 or #18 or
#19 or #20
#22 blood cultur$.mp.
#23 Bacteriological Techniques/mt [Methods]
#24 Blood/mi [Microbiology]
#25 #22 or #23 or #24
#26 #12 and #21 and #25
#27 Animals/
#28 #26 not #27
#29 Viruses/
#30 #28 not #29
#31 limit #30 to (humans and yr¼“2006 -Current”)
mp¼protocol supplementary concept, rare disease supplementary
concept, title, original title, abstract, name of substance word,
subject heading word, unique identiﬁer.
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Backward tracking will be performed by hand-searching
the reference lists of all relevant articles uncovered from
the electronic search and forward tracking using the
keyword ‘SepiFast’ with ISI Citation Indices and Google
Scholar and with a conference proceedings search using
the Web of Science ISI Proceedings (2006 to present).
We will request reference lists held by the only manu-
facturer of the index test (Roche Diagnostics) and
include public-domain clinical diagnostic accuracy data
collected by Roche Diagnostics to ﬁle for the CE mark.
In addition, we will search for unpublished studies
and ongoing trials involving the SeptiFast platform in
the following online registers: http://www.nlm.nih.gov/
hsrproj, http://www.controlled-trials.com/mrct/, http://
portal.nihr.ac.uk/Pages/Portfolio.aspx and http://www.
who.int/trialsearch, with identiﬁed corresponding
authors of eligible trials and content experts contacted to
identify potentially relevant studies and associated data.
Data collection and analysis
Selection of studies (Salford, UK)
The initial selection of titles and abstracts will be
conduct by two review authors (CW and PD) indepen-
dently using the inclusion criteria detailed above. The
full papers of all abstracts deemed eligible (by any
reviewer) will be obtained and read to determine their
inclusion in the review. Disagreement at each step will be
resolved with discussion between the two review authors
(PD and CW) and a third author (GW).
Data extraction and management (Belfast and Warwick, UK)
A standard set of data will be extracted for each study
using a tailored data extraction form which will include
information regarding the inclusion criteria detailed
above, an assessment of the level of evidence using the
Oxford Centre for Evidence-based Medicine Levels
of Evidence
17 and additional information including:
Study design; Clinical setting (ie, community, emergency
department, in-hospital, critical care and general/
specialist); Participant demographics; Clinical features
of included population (illness aetiology); Intercurrent
treatment (antimicrobial therapy); Reference standard
methodology, including contamination rates; Supporting
test results (culture of samples other than blood); Index
test setting (point-of-care, near-patient, clinical or
research laboratory, batched or individual analysis);
Reported index test laboratory failures; Missing partici-
pant data; 2 by 2 table of results for primary
outcome and reported diagnostic accuracy metrics;
Follow-up (eg, survival and length of intensive care and
hospital stay).
Three review authors (DFM, RM and GDP) will inde-
pendently extract data, and any discrepancies will be
resolved by discussion or if necessary by consultation
with a fourth author (BB).
Assessment of methodological quality
Three independent authors (DFM, RM and GDP) will
assess the quality of each individual study using the
checklist (table 3) adapted from the QUADAS tool.
18
Each question on the checklist will be answered with
a yes/no response or noted as unclear if insufﬁcient
information is reported to enable a judgement to be
made, and the reasons for the judgement made will be
documented. Published standard operating procedures
5
and interpretation of the reference standard (blood
culture),
5 including deﬁnitions of blood culture
contamination, will be made available to the indepen-
dent reviewers for reference. In addition, the 2006 CE-
marked index test protocol will be provided to each
reviewer as provided by Roche Diagnostics to purchasers.
Statistical analysis and data synthesis
Data for 232 tables of index test against reference
standard will be extracted from each study. Initially,
these will be plotted as a coupled forest plot of sensitivity
and speciﬁcity, and a scatter plot in ROC space (plotting
sensitivity against 1   specﬁcity for each study). This will
identify any issues of heterogeneity. Summary sensitivity
and speciﬁcity will be estimated using the bivariate
model method
19 because the CE-marked index test is
a semi-quantitative real-time PCR technique and reports
results for the same threshold for positivity.
Investigations of heterogeneity
We will investigate the effects of patient characteristics
(eg, aetiology of sepsis) and infection acquisition
(community vs hospital) on test performance by incor-
porating covariates into the ﬁtted models if sufﬁcient
individual studies are identiﬁed.
Sensitivity analysis
We will explore the potential effects of missing data
using a range of assumptions. This will include the
effects of both missing participant data from included
studies and missing data from studies that did not
provide data in a form that could be extracted and
included in analysis.
Subgroup analysis
If adequate data are available, we will plan two subgroup
analyses of adult versus paediatric populations and
hospital versus community acquired infection.
Assessment of reporting bias
If there are sufﬁcient studies included in analyses, we will
investigate reporting biases using funnel plots based on
effective sample size and regression tests of asymmetry,
as recommended by Deeks and colleagues.
20
DISCUSSION
Blood culture technology is at the centre of evidence-
based guidelines for the investigation and treatment of
patients with sepsis. While culture has been reﬁned over
the last century, it remains insufﬁciently time critical
and cannot assist with early management decisions,
inevitably resulting in wasteful and potentially dangerous
4 Dark P, Wilson C, Blackwood B, et al. BMJ Open 2012;2:e000392. doi:10.1136/bmjopen-2011-000392
Diagnostic accuracy of LightCycler SeptiFast: a systematic reviewTable 3 Format of assessment of methodological quality adapted from QUADAS tool
17
Quality Indicator Notes
1. Was the spectrum of patients
representative of the spectrum of
patients who will receive the test
in practice?
‘Yes’ if the characteristics of the participants are well described and
probably typical of patients with suspected sepsis. ‘No’ if the sample is
unrepresentative of people with suspected sepsis. ‘Unclear’ if the source
or characteristics of participants is not adequately described
2. Were the selection criteria described? 2a ‘Yes’ by international sepsis deﬁnitions,
15 ‘No’ otherwise: 2b ‘Yes’
by some other speciﬁed sepsis deﬁnition ‘No’ otherwise or 2c ‘Unclear’
if insufﬁcient information provided.
3. Is the time period between reference
standard and index test short enough
to be reasonably sure the target
condition did not change between the
two tests
‘Yes’ if reference and index tests performed on blood samples drawn
at the same time. ‘No’ if tests were performed on blood samples taken
at different times. ‘Unclear’ if insufﬁcient information is provided
4. Is partial veriﬁcation avoided? ‘Yes’ if all participants who received the index text also underwent the
reference test. ‘No’ if not all the participants who received the index test
also underwent the reference test. ‘Unclear’ if insufﬁcient information is
provided. If not all participants received the reference tests, how many
did not (of the total)?
5. Is differential veriﬁcation avoided? ‘Yes’ if the same reference test was used regardless of the index test
results. ‘No’ if different reference tests are used depending on the results
of the index test. ‘Unclear’ if insufﬁcient information is provided.
If any participants received a different reference test, what were the
reasons stated for this, and how many participants were involved?
6. Was the execution of the index
test done in accordance with the
CE-mark protocol?
‘Yes’ as per CE-marked protocol described by manufacturer
(Roche Diagnostics) from January 2006. ‘No’ if CE-mark protocol
breached. ‘Unclear’ if insufﬁcient information provided. (CE-marked
protocol will be provided to the independent reviewers).
7. Was the execution of the
reference standard described in
sufﬁcient detail to permit its replication?
‘Yes’ if clinical standard described and is consistent with published
standard operating procedures.5 ‘No’ if reference standard falls short
of standard operating procedures.5 ‘Unclear’ if insufﬁcient information
provided. Also comment on how culture contaminations were deﬁned
and reported?
8. Are the reference standard test
results blinded?
‘Yes’ if the report stated that the person undertaking the reference test
did not know the results of the index tests, or if the two tests were
carried out in different places. ‘No’ if the report stated that the same
person performed both tests, or that the results of the index tests
were known to the person undertaking the reference tests. ‘Unclear’
if insufﬁcient information provided.
9. Are the index test results blinded? ‘Yes’ if the report stated that the person undertaking the index test
did not know the results of the reference tests, or if the two tests were
carried out in different places. ‘No’ if the report stated that the same
person performed both tests, or that the results of the index tests
were known to the person undertaking the reference tests. ’Unclear’
if insufﬁcient information provided.
10. Were uninterpretable results reported? ‘Yes’ if the number of participants in the two-by-two table
matches the number of participants recruited into the study, or
if sufﬁcient explanation is provided for any discrepancy. ‘No’ if the
number of participants in the two-by-two table does not match the
number of participants recruited into the study, and insufﬁcient
explanation is provided for any discrepancy. ‘Unclear’ if insufﬁcient
information is given to permit judgement. Report how many results
were uninterpretable (of the total).
11. Were any withdrawals explained? ‘Yes’ if there are no participants excluded from the analysis, or if
exclusions are adequately described. ‘No’ if there are participants
excluded from the analysis and there is no explanation given.
‘Unclear’ if not enough information is given to assess whether any
participants were excluded from the analysis. Report how many
participants were excluded from the analysis, for reasons other
than uninterpretable results.
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based technologies have become standard laboratory
techniques over the last two decades and could deliver
real opportunity in terms of sensitivity and speed of
pathogen detection in the clinical setting of life-threat-
ening infection. LightCycler SeptiFast is the ﬁrst PCR-
based system to be awarded a CE-mark for pathogen
detection and identiﬁcation in blood samples and, to
date, is the most intensively investigated multiplex real-
time PCR assay in the clinical setting of sepsis. The
purpose of our planned systematic review is to deter-
mine, for the ﬁrst time, the clinical diagnostic accuracy
of this real-time PCR technology as part of an NIHR-
funded HTA of this technology in the setting of poten-
tially life-threatening infections. Based on the results of
this non-commercial systematic review, independent
recommendations will be made to the National Health
Service providers as to whether LightCycler SeptiFast
has sufﬁcient clinical diagnostic accuracy to move
forward to efﬁcacy and effectiveness testing during the
provision of routine patient care.
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